Results from the Phase III NRG Oncology NRG-GU003 clinical trial comparing hypofractioned post-prostatectomy radiotherapy (HYPORT) to conventionally fractioned post-prostatectomy radiotherapy (COPORT) ...

SAN FRANCISCO--(BUSINESS WIRE)--ArteraAI, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, announced the validation of its first multimodal artificial ...

The authors of a recent review compared guidelines from several world regions. Post-prostatectomy urinary incontinence guidelines vary in their recommendations following a comprehensive patient ...

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study Both the performance ...

PORTOS gene signature as a predictor of risk of adverse events after dose-escalated vs. lower-dose prostate radiation therapy in NRG/RTOG 0126. Five-year changes in urinary function and prostate ...

The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...

NEW YORK (Reuters Health) - Younger age, symptoms of depression, and severe pain during the immediate post-operative period are significant predictors of severe pain during recovery from radical ...

(HealthDay News) — For patients with prostate cancer treated with radical prostatectomy (RP) and post-prostatectomy image-guided intensity-modulated radiotherapy (IG-IMRT), decision regret (DR) is ...